Literature DB >> 16023783

Roles and regulation of Wnt signaling and beta-catenin in prostate cancer.

Meletios Verras1, Zijie Sun.   

Abstract

The Wnt signaling pathway and its key component beta-catenin play critical roles in embryonic development as well as in human diseases, including various malignancies. Accumulated evidence has demonstrated a significant role for the Wnt pathway in the development and progression of human prostate cancer. The recent discovery of an interaction between beta-catenin and the androgen receptor (AR) suggests a possible mechanism of cross talk between Wnt and androgen signaling pathways. In this review, we summarize the recent progresses in this interesting and growing field. Particularly, we focus on the observation that the activation of the Wnt-mediated signal occurs in a different manner in prostate cancer than in colorectal cancer or other human malignancies. Since mutations in Adenomatous polyposis coli (APC), beta-catenin, and other components of the beta-catenin destruction complex are rare in prostate cancer cells, other regulatory mechanisms appear to play dominant roles in the activation of beta-catenin, such as loss or reduction of E-cadherin, a component of cell adhesion complex, and abnormal expression of Wnt ligands, receptors, inhibitors, and other co-regulators. Understanding the role and regulation of the Wnt signaling pathway in prostate cancer cells may help identify new targets for the prostate cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16023783     DOI: 10.1016/j.canlet.2005.06.004

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  92 in total

1.  Activation of β-catenin signaling in androgen receptor-negative prostate cancer cells.

Authors:  Xinhai Wan; Jie Liu; Jing-Fang Lu; Vassiliki Tzelepi; Jun Yang; Michael W Starbuck; Lixia Diao; Jing Wang; Eleni Efstathiou; Elba S Vazquez; Patricia Troncoso; Sankar N Maity; Nora M Navone
Journal:  Clin Cancer Res       Date:  2012-02-01       Impact factor: 12.531

2.  Mesd is a universal inhibitor of Wnt coreceptors LRP5 and LRP6 and blocks Wnt/beta-catenin signaling in cancer cells.

Authors:  Wenyan Lu; Chia-Chen Liu; Jaideep V Thottassery; Guojun Bu; Yonghe Li
Journal:  Biochemistry       Date:  2010-06-08       Impact factor: 3.162

3.  Transglutaminase 2 as a novel activator of LRP6/β-catenin signaling.

Authors:  S Deasey; D Nurminsky; S Shanmugasundaram; F Lima; M Nurminskaya
Journal:  Cell Signal       Date:  2013-08-29       Impact factor: 4.315

4.  Genetic interactions of the androgen and Wnt/beta-catenin pathways for the masculinization of external genitalia.

Authors:  Shinichi Miyagawa; Yoshihiko Satoh; Ryuma Haraguchi; Kentaro Suzuki; Taisen Iguchi; Makoto M Taketo; Naomi Nakagata; Takahiro Matsumoto; Ken-ichi Takeyama; Shigeaki Kato; Gen Yamada
Journal:  Mol Endocrinol       Date:  2009-03-12

5.  The beta-catenin binding protein ICAT modulates androgen receptor activity.

Authors:  Ming Zhuo; Chunfang Zhu; JingLucy Sun; William I Weis; Zijie Sun
Journal:  Mol Endocrinol       Date:  2011-09-01

6.  Lupeol inhibits proliferation of human prostate cancer cells by targeting beta-catenin signaling.

Authors:  Mohammad Saleem; Imtiyaz Murtaza; Rohinton S Tarapore; Yewseok Suh; Vaqar Mustafa Adhami; Jeremy James Johnson; Imtiaz Ahmad Siddiqui; Naghma Khan; Mohammad Asim; Bilal Bin Hafeez; Mohammed Talha Shekhani; Benyi Li; Hasan Mukhtar
Journal:  Carcinogenesis       Date:  2009-02-20       Impact factor: 4.944

7.  Activation of beta-Catenin in mouse prostate causes HGPIN and continuous prostate growth after castration.

Authors:  Xiuping Yu; Yongqing Wang; Ming Jiang; Brian Bierie; Pradip Roy-Burman; Michael M Shen; Makoto Mark Taketo; Marcia Wills; Robert J Matusik
Journal:  Prostate       Date:  2009-02-15       Impact factor: 4.104

8.  Axin2 expression identifies progenitor cells in the murine prostate.

Authors:  Christopher S Ontiveros; Sarah N Salm; E Lynette Wilson
Journal:  Prostate       Date:  2008-09-01       Impact factor: 4.104

9.  Targeting the Wnt/β-catenin pathway in primary ovarian cancer with the porcupine inhibitor WNT974.

Authors:  Jonathan D Boone; Rebecca C Arend; Bobbi E Johnston; Sara J Cooper; Scott A Gilchrist; Denise K Oelschlager; William E Grizzle; Gerald McGwin; Abhishek Gangrade; J Michael Straughn; Donald J Buchsbaum
Journal:  Lab Invest       Date:  2015-12-14       Impact factor: 5.662

10.  Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530.

Authors:  Y-M Chang; L Bai; S Liu; J C Yang; H-J Kung; C P Evans
Journal:  Oncogene       Date:  2008-08-04       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.